Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
|Articles|January 10, 2005
JP at Large: The Internet patient
A customer engaged me in a lengthy conversation about his prescription. He had taken it for a few weeks and was concerned about the side effects. "Is IBS one of the side effects?" he asked.
Advertisement
Advertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5